News about Drug Discovery & Development

MinervaX Partners with Wacker Biotech for Prophylactic Vaccine

MinervaX has joined forces with Wacker Biotech to manufacture MinervaX's active protein ingredients of its GBS vaccine.

Drug Discovery & Development | 18/09/2024 | By Aishwarya |  555

Somite Therapeutics Receives FDA Orphan Drug and RPDD Designations for SMT-M01

Somite Therapeutics' SMT-M01 program leverages the company's proprietary AlphaStem AI platform to develop a novel cell replacement therapy for DMD.

Drug Discovery & Development | 17/09/2024 | By Aishwarya |  842

C2 PHARMA Rolls Outs Naphazoline Hydrochloride

Naphazoline HCL is effective in alleviating red eyes and nasal congestion, making it suitable for both prescription and over-the-counter products.

Drug Discovery & Development | 16/09/2024 | By Aishwarya |  726

GC Cell Signs Licensing Deal with PT Bifarma Adiluhung for Immuncell-LC

Bifarma is recognized for operating Indonesia's first GMP-certified cell therapy production facility and possesses a comprehensive sales and marketing infrastructure focused on oncology, specializing in a cold chain distribution network that spans across Indonesia.

Drug Discovery & Development | 11/09/2024 | By Aishwarya |  656

Seegene Unveils New mpox RUO PCR Assays for Clade 1

Seegene Inc. has announced to launch a new type of research-use-only (RUO) PCR assay to address the spread of the monkeypox virus variant, Clade Ib, which is currently prevalent in Africa.

Drug Discovery & Development | 10/09/2024 | By Aishwarya |  203

Sun Pharma and Moebius Medical Receive FTD for MM-II for Treatment of Osteoarthritis Knee Pain

Sun Pharma and Moebius Medical have announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain.

Drug Discovery & Development | 07/09/2024 | By Aishwarya |  356

Lupin Unveils Mirabegron Extended-Release Tablets in US

Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 50 mg of Astellas Pharma Global Development, Inc.

Drug Discovery & Development | 06/09/2024 | By Aishwarya |  510

Strides Gets FDA Approval for Theophylline Extended-Release Tablets

Theophylline Extended-Release Tablets, 300 mg and 450 mg have a combined market size of ~USD 11.5 million, with the 300 mg dosage contributing ~USD 10.8 million.

Drug Discovery & Development | 06/09/2024 | By Aishwarya |  562

Alembic Pharma Receives Final FDA Approval for Albendazole Tablets

Albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Drug Discovery & Development | 05/09/2024 | By Aishwarya |  975

Lilly Signs Deal with EVA Pharma to Expand Access to baricitinib

This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030.

Drug Discovery & Development | 05/09/2024 | By Aishwarya |  656